Lyon, France, June 1, 2017 8: 00am – POXEL SA (Euronext POXEL – FR0012432516), a biopharmaceutical company specializing in the development of innovative treatments against metabolic diseases, including type 2 diabetes, today announces its participation in the conference Jefferies London Healthcare 2017 in New York, and the Forum Kepler Cheuvreux Biotech in Paris.
Download the free guide
Boost your gains
The conference organised by Jefferies, will be held from 6 to 9 June 2017 at the Grand Hyatt New York in New York, United States. The Company invites investors to a general presentation of its activities on the 6th of June at 16: 00 (New York time), in the #1 Ballroom, and will be available to speak with them in individual meetings. The presentation will be broadcast live on the Internet. You can access it through this link : http://wsw.com/webcast/jeff105/poxel.pa.
The retransmission is deferred will be available for 90 days after the presentation.
The Forum Kepler Cheuvreux Biotech will be held on 8 and 9 June 2017 in the premises of Kepler Cheuvreux, 112, avenue Kléber 75116 Paris. Poxel will be held at the disposal of investors to maintain up together with them in the framework of individual meetings.
About Poxel – www.poxel.com
Poxel is based on its level of development expertise in metabolism to develop and enhance a portfolio of drug candidates, currently focused on type 2 diabetes. We have completed the development of phase 2 in the United States and Europe our product is the most advanced, the Imeglimine, the first of a new class of therapeutic targeting of the mitochondrial dysfunction, and which entered into clinical development to phase 2b in japanese patients. We are continuing the development of our 2nd program, the PXL770, an activator direct AMPK. We intend to generate growth through strategic partnerships and the development of our portfolio.
Download the free guide
Boost your gains
